Danish pharmaceutical giant Novo-Nordisk A/S announced on Wednesday the expansion of its cooperation with AI biotechnology company Valo Health, aiming to accelerate the development of new therapies for cardiac metabolic diseases. Under the new agreement, both parties will jointly advance 20 new drug projects, covering cardiovascular diseases, obesity, and type 2 diabetes. Valo is expected to receive about $4.6 billion in milestone payments, as well as additional research and development funding and royalties.
诺和诺德与Valo Health扩大合作 46亿美元巨资共研心脏代谢新药
Novo-Nordisk A/S expands cooperation with Valo Health, investing a massive $4.6 billion in the joint research of new drugs for cardiac metabolism.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha